Dogwood Therapeutics (NASDAQ:DWTX) Given “Buy” Rating at HC Wainwright

Dogwood Therapeutics (NASDAQ:DWTX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $12.00 target price on the stock.

Separately, Weiss Ratings lowered Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.00.

Dogwood Therapeutics Stock Performance

Shares of DWTX opened at $1.70 on Tuesday. The company has a 50-day simple moving average of $2.07 and a 200-day simple moving average of $3.59. Dogwood Therapeutics has a 52 week low of $1.28 and a 52 week high of $9.50. The firm has a market capitalization of $56.78 million, a P/E ratio of -0.16 and a beta of 1.68.

Dogwood Therapeutics (NASDAQ:DWTX) last released its earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. As a group, equities analysts forecast that Dogwood Therapeutics will post -0.93 earnings per share for the current year.

Institutional Trading of Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. 9.05% of the stock is owned by institutional investors.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.